|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Coexistence of BRAF V600E and TERT promoter mutations was particularly associated with high-risk clinicopathological features, as exemplified by extrathyroidal invasion seen in 54.5% (12/22) of patients harboring both mutations versus 9.9% (23/232) of patients harboring neither mutation (P < 0.001).
|
26943032 |
2016 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
One case not meeting criteria for NIFTP maintained the diagnosis of encapsulated FVPTC without invasion but demonstrated significant mitotic activity (three mitoses/ten HPF) and lacked lymph node metastases and BRAF V600E mutation.
|
29368294 |
2018 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF (V600E) causes upregulation of tissue inhibitor of metalloproteinase-1 (TIMP-1), which promotes cell invasion in papillary thyroid carcinoma (PTC).
|
23893334 |
2013 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, over-expression of (V600E)BRAF increases migration and invasion of wild-type BRAF thyroid cells.
|
23435375 |
2013 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, statistically significant correlations of BRAF(V600E) with indicators of tumor aggressiveness such as thyroid capsular invasion, multifocality, lymph node metastasis, and extrathyroidal spread were found.
|
22426956 |
2012 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
On univariate analysis, the BRAF(V600E) mutation was associated with extrathyroidal extension (P = .009) and variants of PTC (P = .019), but a high-risk Metastasis, Patient Age, Completeness of resection, local Invasion and Tumor Size (MACIS) score (≥ 6) (P = .146) and lymph node metastasis (P = .628) were not significantly associated with the BRAF(V600E) mutation.
|
21803329 |
2012 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
We find that metastatic BRAF(V600E)-PTC cells elicit paracrine-signaling which trigger migration of pericytes, blood endothelial cells and lymphatic endothelial cells as compared to BRAF(WT)-PTC cells, and show a higher rate of invasion.
|
26636651 |
2015 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
The association between BRAF((V600E)) and extra-thyroid invasion</span> was also found in micro-PTCs (P=0.006).
|
18310287 |
2008 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis.
|
20498063 |
2010 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
|
22105775 |
2012 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Considering all tumor foci, the all BRAF(V600E) mutation group exhibited a younger population (P = .039), showed increased extrathyroidal invasion (38.8% vs 14.7%, P = .017) and lymph node metastasis (71.4% vs 48.4%, P = .038), and received more radioactive iodine therapy (79.2% vs 52.9%, P = .012) than the mixed BRAF(V600E) mutation group.
|
24612623 |
2014 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, in multivariate COX analysis, the association remained significant only for CA125 levels (vs. ⩽ 35 u/ml group, HR 3.341; 95% CI, 1.198-9.316; P= 0.0212), vascular invasion (vs. negative vascular invasion, HR, 2.349; 95% CI, 1.227-4.499; P= 0.01), and BRAF (V600E) (vs. wild Braf, HR, 7.794; 95% CI, 1.867-32.531; P= 0.0049).
|
29562502 |
2018 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
In contrast, age- and size-matched classic papillary microcarcinomas (n=26) showed no extrathyroidal extension (p=0.002), lymphovascular invasion in 1, central compartment lymph node metastasis in 2, lateral cervical node metastasis in 1, multifocal tumors in 10 (38.5%), the BRAF(V600E) mutation in 20 (76.9%), and it infrequently presented in stage III/IVA (7.7%, p=0.02).
|
23682579 |
2013 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results provide support for the role of BRAF(V600E) in metastasis and suggest that inhibiting invasion is a potential therapeutic strategy against melanoma.
|
27210749 |
2016 |
|
rs121913377
|
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis confirmed significant associations between BRAF(V600E) mutation and female gender, multifocality, ETE, LNM, TNM stage, concomitant hashimoto thyroiditis, vascular invasion and recurrence/persistence, suggesting the predictive value of BRAF(V600E) mutation for PTC prognosis.
|
26871894 |
2016 |